KDR and neoplasm: Sorafenib can target Raf kinase and block the Ras/Raf/mitogen-activated protein kinases (MAPK) pathway and directly inhibit tumor cell proliferation, it can inhibit the activity of multiple receptors such as vascular endothelial-derived growth factor (VEGF) −2 and VEGFR receptor (VEGFR)-3 to inhibit tumor angiogenesis, and play a dual role of anti-tumor cell proliferation and anti-angiogenesis [6].